Sherry M. Wren

Sherry M. Wren

Auto-generated profile, based on publicly available information

Sherry M. Wren

Department of Surgery, Stanford University School of Medicine, Stanford, USA

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2012 in Chest
Verified
Journal Article
Closed access
MGMichael K. Gould
Michael K. Gould
DGDavid A. Garcia
David A. Garcia
SWSherry M. Wren
Sherry M. Wren
PKPaul J. Karanicolas
Paul J. Karanicolas
JAJuan I. Arcelus
Juan I. Arcelus
CSCharles M. Samama
Charles M. Samama

6 October 2015 in JAMA
Verified
Journal Article
Open access
PDF file
JFJames Fleshman
James Fleshman
MBMegan Branda
Megan Branda
DSDaniel J. Sargent
Daniel J. Sargent
ABAnne Marie Boller
Anne Marie Boller
VGVirgilio George
Virgilio George
HNHeidi Nelson
Heidi Nelson
Quiz Ref ID Treatment of curable, locally advanced (stage II or III) rectal cancer relies on surgical resection as the core feature of a multimodality treatment process.1,2 Surgical resection remains the most important treatment modality for rectal cancer in terms of a curative resection, staging, prognosis, and subsequent therapeutic decisions.3 Surgical integrity of the specimen and tumor pathologic staging is the most important prognostic factor in development of recurrent rectal cancer.4 Total mesorectal excision completeness has become a marker for a good surgical technique and predicts the likelihood of local recurrence of the cancer in the pelvis.5,6

3 February 2017 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
JPJ T Powell
J T Powell
MSM J Sweeting
M J Sweeting
PUP Ulug
P Ulug
JBJ D Blankensteijn
J D Blankensteijn
FLF A Lederle
F A Lederle
CCC Cousins
C Cousins
The erosion of the early mortality advantage of elective endovascular aneurysm repair (EVAR) compared with open repair of abdominal aortic aneurysm remains without a satisfactory explanation. An individual-patient data meta-analysis of four multicentre randomized trials of EVARversus open repair was conducted to a prespecified analysis plan, reporting on mortality, aneurysm-related mortality and reintervention. The analysis included 2783 patients, with 14 245 person-years of follow-up (median 5·5 years). Early (0–6 months after randomization) mortality was lower in the EVAR groups (46 of 1393 versus 73 of 1390 deaths; pooled hazard ratio 0·61, 95 per cent c.i. 0·42 to 0·89; P = 0·010), primarily because 30-day operative mortality was lower in the EVAR groups (16 deaths versus 40 for open repair; pooled odds ratio 0·40, 95 per cent c.i. 0·22 to 0·74). Later (within 3 years) the survival curves converged, remaining converged to 8 years. Beyond 3 years, aneurysm-related mortality was significantly higher in the EVAR groups (19 deaths versus 3 for open repair; pooled hazard ratio 5·16, 1·49 to 17·89; P = 0·010). Patients with moderate renal dysfunction or previous coronary artery disease had no early survival advantage under EVAR. Those with peripheral artery disease had lower mortality under open repair (39 deaths versus 62 for EVAR; P = 0·022) in the period from 6 months to 4 years after randomization. The early survival advantage in the EVAR group, and its subsequent erosion, were confirmed. Over 5 years, patients of marginal fitness had no early survival advantage from EVAR compared with open repair. Aneurysm-related mortality and patients with low ankle : brachial pressure index contributed to the erosion of the early survival advantage for the EVAR group. Trial registration numbers: EVAR-1, ISRCTN55703451; DREAM (Dutch Randomized Endovascular Aneurysm Management), NCT00421330; ACE (Anévrysme de l'aorte abdominale, Chirurgie versus Endoprothèse), NCT00224718; OVER (Open Versus Endovascular Repair Trial for Abdominal Aortic Aneurysms), NCT00094575.

1 July 1985 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
SIS T Ildstad
S T Ildstad
SWS M Wren
S M Wren
JBJ A Bluestone
J A Bluestone
SBS A Barbieri
S A Barbieri
DSD H Sachs
D H Sachs
Mixed allogeneically reconstituted mice (B10 + B10.D2----B10) that specifically accept B10.D2 tail skin allografts were examined for in vivo and in vitro immunocompetence, patterns of hematopoietic repopulation, and in vitro reactivity. In vitro, mixed allogeneic chimeras (B10 + B10.D2----B10) manifested specific tolerance in mixed lymphocyte reactions and cell-mediated lympholysis to B10 and B10.D2 splenocytes, with normal responses to third-party (B10.BR) cells. Such chimeras were immunocompetent in B cell and helper T cell responses, as assessed by their primary plaque forming cell responses to in vivo sheep red blood cell immunization. This is in contrast to fully allogeneic chimeras, which responded less well. In addition, survival of the mixed allogeneic chimeras in a conventional animal facility was superior to that of fully allogeneic chimeras, and similar to syngeneically reconstituted (B10----B10) mice. Specific tolerance to skin grafts, degree of allogeneic engraftment, and persistence of chimerism was also assessed in a noncongenic mixed allogeneic combination (B10 + C3H----B10). Such animals manifested specific hyporeactivity to C3H skin allografts, but eventual chronic rejection of the grafts occurred in spite of stable and persistent mixed chimerism. MHC-congenic (B10.BR) skin grafts were accepted indefinitely in the same animals, suggesting that skin-specific non-major histocompatibility complex antigens were responsible for rejection of the C3H skin allografts.

8 December 2021 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
AMAviva S. Mattingly
Aviva S. Mattingly
LRLiam Rose
Liam Rose
HEHyrum S. Eddington
Hyrum S. Eddington
ATAmber W. Trickey
Amber W. Trickey
MCMark R. Cullen
Mark R. Cullen
SWSherry M. Wren
Sherry M. Wren
In February 2020, US physicians and public health personnel watched in real time the mounting deaths among patients and health care workers with COVID-19 and the associated resource shortages in Europe.1,2 Soon thereafter, the New York City metropolitan area became the first US epicenter for COVID-19. The most recent pandemic the US had faced, the 2009 influenza A (H1N1) virus pandemic was associated with mortality (0.02%) and hospitalization (0.45%) rates of less than one-half of 1 percent of the estimated 60.8 million people infected.3 In contrast, COVID-19 was associated with unprecedented stress and demands on the New York City health system, with increased rates of mortality (9.6%) and hospitalization (26.6%).4 On March 13, 2020, the US president declared a national emergency, leading to a shutdown of all nonessential activities throughout the United States.5 The American College of Surgeons (ACS) and other major surgical specialty societies recommended minimizing, postponing, or canceling elective surgical procedures in mid-March and published guidelines for triage of elective procedures by surgical specialty.6,7 The Centers for Medicare & Medicaid Services (CMS) and US Surgeon General also issued statements and recommendations for postponement of nonessential surgical procedures.6,8 Recommendations were driven by concerns that continuation of elective surgical treatments could potentially compromise hospital and intensive care unit (ICU) capacity and result in shortages in personal protective equipment (PPE) supplies. In line with national recommendations, 35 states had formal declarations by state governors or medical societies to postpone all nonessential surgical procedures, which was associated with a decrease in surgical procedure volume during the initial months of the pandemic shutdown.9

1 September 2013 in JAMA Surgery
Verified
Journal Article
Open access
PDF file
KHKimberly Hwa
Kimberly Hwa
SWSherry M. Wren
Sherry M. Wren
Delivery of surgical care that is more efficient and cost-effective and has a high degree of patient satisfaction with excellent outcomes is a necessary evolution of the current surgical practice model. An in-person postoperative clinic evaluation is the “gold standard” throughout the United States. Some practices such as Kaiser Permanente use allied health care providers in lieu of surgeons to see the postoperative patients (N. Baril, MD, oral communication, December 12, 2012). The Veterans Health Care System provides care to eligible patients who come from sizeable catchment areas. The patients often must travel significant distances, which represent an investment on their part of time, missed work, and travel costs for a postoperative clinic visit that is typically quite brief. Therefore, as a quality initiative, we examined whether an allied health professional telephone visit could safely substitute for an in-person clinic visit.